MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program

被引：0

作者：

Brassat, David ^{[1
]}

Hautecoeur, Patrick ^{[2
]}

Durand-Dubief, Francoise ^{[3
]}

Castelnovo, Giovanni ^{[4
]}

Derache, Nathalie ^{[5
]}

Bourre, Bertrand ^{[6
]}

Donze, Cecile ^{[2
]}

Ouallet, Jean-Christophe ^{[7
]}

Collongues, Nicolas ^{[8
]}

Simon, Olivier ^{[9
]}

Brion, Guillaume ^{[9
]}

Sedel, Frederic ^{[9
]}

Vermersch, Patrick ^{[10
]}

Lasser, Robert ^{[9
]}

Morteau, Olivier ^{[9
]}

机构：

[1] Univ Hosp Toulouse, Toulouse, France

[2] Catholic Inst Lille, Groupement Hop, Lomme Les Lille, France

[3] Pierre Wertheimer Hosp, Rhone, France

[4] Caremeau Hosp, Rhone, France

[5] CHU Caen, Caen, France

[6] Rouen Normandy Univ, Rouen, France

[7] Univ Bordeaux, Bordeaux, France

[8] Univ Hosp Strasbourg, Strasbourg, France

[9] MedDay Pharmaceut, Paris, France

[10] Univ Lille, Lille, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P046

引用

页码：31 / 32

页数：2

共 50 条

[11] High dose pharmaceutical grade biotin (MD1003) protects axons in a TMEV-induced mouse model of progressive multiple sclerosis
Warrington, A.
Perdomini, M.
Bernard, D.
Rodriguez, M.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 532 - 533
[12] High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration
Nessler, S.
Winkler, A.
van der Meer, F.
Gargareta, S.
Cobos, A.
Stadelmann, C.
Nave, K. A.
Brueck, W.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 311 - 311
[13] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
Ciron, J.
Pignolet, B.
Bucciarelli, F.
Biotti, D.
Lerebours, F.
Dorcet, G.
Rabadeux, C.
Freitas, N.
Bonneville, F.
Brassat, D.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
[14] Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis
Donze, C.
Guyot, M. A.
Kwiatkowski, A.
Hautecoeur, P.
Massot, C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 385 - 385
[15] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores
Papeix, C.
Lebrun-Frenay, C.
Defer, G.
Labauge, P.
Ruiz, M.
Simon, O.
Tourbah, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 938 - 939
[16] Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-up data
Vukusic, S.
De Seze, J.
Edan, G.
Moreau, T.
Brochet, B.
Lasser, R.
Tourbah, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 401 - 402
[17] Effect of MD1003 (high dose pharmaceutical grade biotin) in progressive MS: design and baseline data from the phase III SPI2 study
Cree, B. A. C.
Cutter, G.
Wolinsky, J. S.
Freedman, M. S.
Comi, G.
Giovannoni, G.
Hartung, H. P.
Sedel, F.
Lublin, F.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 692 - 693
[18] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
Cree, Bruce A. C.
Cutter, Gary
Wolinsky, Jerry S.
Freedman, Mark S.
Comi, Giancarlo
Giovannoni, Gavin
Hartung, Hans-Peter
Sedel, Frederic
Lublin, Fred
[J]. NEUROLOGY, 2020, 94 (15)
[19] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months
De Seze, Jerome
Edan, Gilles
Moreau, Thibault
Brochet, Bruno
Sedel, Frederic
Tourbah, Ayman
[J]. NEUROLOGY, 2019, 92 (15)
[20] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data
De Seze, J.
Edan, G.
Moreau, T.
Brochet, B.
Sedel, F.
Tourbah, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 287 - 288

← 1 2 3 4 5 →